1094 Favorable preclinical efficacy and safety profile of AVB-001 a novel IL-2 cell-based immunotherapy that eradicates ovarian cancer in mouse tumor models and supports first in human clinical development

Guillaume Carmona, Omid Veiseh, Ryan Newman et al.|Regular and Young Investigator Award Abstracts|2022

Cited by 0